Stocktoria
EXOZYMES INC. EXOZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2024-11-13
Chart by TradingView
1/9
Piotroski F — financial health
-18.46
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | — | — | $70,069 |
| Operating income | -$9.7M | -$5.9M | -$1.8M |
| Net income | -$9.2M | -$5.9M | -$2.0M |
| Operating cash flow | -$6.5M | -$8.5M | -$1.2M |
| Free cash flow | -$6.7M | -$8.9M | -$1.5M |
| Total assets | $6.0M | $13.0M | $3.6M |
| Total liabilities | $2.6M | $2.6M | $3.9M |
| Shareholders' equity | $3.4M | $10.4M | -$384,319 |
| Ratios | |||
| Operating margin | — | — | -2563.5% |
| Net margin | — | — | -2909.1% |
| FCF margin | — | — | -2097.3% |
| Return on assets | -153.4% | -45.0% | -57.3% |
| Return on equity | -269.6% | -56.2% | 530.4% |
| Current ratio | 2.51 | 8.12 | 0.50 |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -18.46 (distress)
- Working capital / assets 0.397
- Retained earnings / assets -3.534
- EBIT / assets -1.627
- Equity / liabilities 1.32
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0002010788 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.